R Moroose

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio et al. · Annals of Oncology · 2021 · 375 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat et al. · Annals of Oncology · 2020 · 145 citations · Full text

Medicine, Oncology, Pharmacology +17

Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases

JA Sadowski, BC Furie, R Moroose et al. · Blood · 1990 · 98 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Gabriel N. Hortobágyi, Joohyuk Sohn, F. Melo Cruz et al. · Annals of Oncology · 2024 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

Sara A. Hurvitz, Mark D. Pegram, L. S. Lin et al. · Cancer Research · 2009 · 54 citations

Medicine, Oncology, Pharmacology +17